Global pharmaceutical companies are ramping up pressure on European governments over healthcare spending controls. Germany has become the latest focal point of intense industry resistance. Drugmakers facing tighter financial regulations across Europe are deploying a familiar strategy. They are warning policymakers that local investments, facility expansions, and patient access to life-saving medicines are at risk. This playbook recently delivered major…
Tag: Drug Pricing
-
German Drug Price Reforms Shake Pharma And Hospitals
Germany’s cost-of-care debate is moving from rhetoric to legislation. And it is landing hard on medicines and hospitals. The latest discussions on German drug price reforms come as Berlin is trying to stabilise statutory health insurance funds that are projected to drift deeper into deficit. Government estimates put the potential shortfall at around €40bn by 2030 if spending is not…
-
Generic Semaglutide Pricing Could Disrupt Global Markets
New research reveals that manufacturers could sell generic versions of Novo Nordisk’s blockbuster drugs, Ozempic and Wegovy, for less than $3 a month. This study highlights a massive gap between current list prices and actual production costs. It suggests a future where powerful weight-loss treatments are accessible to billions. The Massive Gap In Generic Semaglutide Pricing Researchers at the University…
-
FDA Biosimilar Development Guidance Targets Treatment Costs
\n\nBiologic medicines are made from living cells and are among the most expensive therapies available. While they account for only 5% of all prescriptions, they are responsible for a staggering 51% of total drug spending in the United States. To address this imbalance, the FDA is prioritising the expansion of the biosimilar market.\n\n\n\nThe new FDA biosimilar development guidance focuses on…
-
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and diabetes medicines. For Q4, Lilly…
-
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is gearing up to launch one of the world’s first generic semaglutide in Canada, capitalising on the recent loss of patent protection for Novo Nordisk’s blockbuster GLP‑1 weight‑loss injection. The move could be a pivotal moment for access and competition in an increasingly lucrative market. Canada’s early patent expiry of semaglutide has drawn global attention. Industry leaders see…
-
1.4% SEP Increase Impacts Pharmaceutical Investment
The pharmaceutical sector has issued a strident, urgent plea to the Health Department. They are imploring officials to immediately reconsider the newly gazetted 1.4% SEP increase in the maximum Single Exit Price (SEP) for medicines in 2026. The adjustment, set at a mere 1.47%, is a significant blow to the industry. They had anticipated an increase more than double that…
-
Pfizer Drug Pricing Deal Sees Stocks Soar
In a move heralded by President Donald Trump as a monumental victory for American consumers, pharmaceutical giant Pfizer has agreed to a deal that promises to slash the prices of some of its drugs. However, the market’s reaction has told a very different story. This reaction raises questions about the actual impact of the agreement on the firm’s bottom line…
-
Trump’s Tariff Stick Won’t Bring Generic Drug Manufacturing Home
President Donald Trump’s administration has championed Trump’s Tariff Stick as a means to compel global industries to relocate manufacturing to the United States. However, for the generic drug sector, which supplies roughly 90% of all medicines consumed by Americans, Trump’s Tariff Stick is a blunt instrument with potentially damaging outcomes. Industry leaders are cautioning that, instead of encouraging domestic production,…
-
Are New Cancer Treatments Worth the Price?
A significant number of cancer drugs approved since 2000, as reviewed by Bloomberg News, have never been definitively shown to extend patient survival for their approved uses. This raises questions about the growing cost of cancer treatments. The landscape of cancer treatment has been revolutionized over the past three decades, with over 200 new cancer drugs greenlit by the US…
-
Trump targets drug costs in sweeping executive order
US President Donald Trump has signed a wide-ranging executive order. It targets drug costs by directing pharmaceutical companies to lower their prices. The goal is to align with rates paid in other developed countries. This executive order marks a clear initiative where Trump targets drug costs. It fulfills a key campaign promise. The move was met with scepticism from analysts…